ANIMALHEALTHX Weekly is your weekly pulse on the global animal health industry, delivering curated insights, executive interviews, regulatory updates, innovation breakthroughs, and market movements shaping the future of veterinary medicine and animal care.
Feature Story
- Ethical Treatment of Animals: Advancing Compassion, Welfare, and Responsible Care
Cover Story
- Gallant Advances Stem Cell Therapy for Canine Osteoarthritis with Positive Pilot Data and FDA Pathway Eligibility
Product Launches & Wellness Innovations
- Jaguar Health Expands Neonorm Franchise with Plant-Based Digestive Health Product for Dogs
- PetMade Launches Veterinarian-Approved Cardiovascular Support Supplements for Dogs
Brand & Consumer Health Initiatives
- Pet Honesty Launches The Honest Difference to Elevate Standards in Pet Supplements
Diagnostics & Research Breakthroughs
- VolitionRx Advances Liquid Biopsy Breakthrough for Feline Cancer Detection
Sustainability & Animal Nutrition
- Phibro Launches Sustainability Platform to Decarbonize Animal Protein and Petfood Supply Chains
Gallant Advances Stem Cell Therapy for Dogs
Regulatory Milestone
Gallant has received eligibility from the US FDA CVM for the expanded conditional approval pathway for its intravenous uterine-derived mesenchymal stromal cell (UMSC) therapy for canine osteoarthritis, with conditional approval targeted for 2028.
Key Highlights
- In a randomized, blinded, placebo-controlled pilot study, 88 client-owned dogs with radiographically confirmed OA received two IV doses of donor-derived UMSCs or placebo 14 days apart and were followed through Day 90.
- Dogs treated with UMSCs showed statistically significant improvement versus placebo in validated pet parent-reported outcome measures at Days 60 and 90, with pet owner and veterinarian assessments of mobility, pain, and quality of life consistently favoring the treated group.
- No treatment-related serious adverse events were observed, and early findings support the safety of repeat IV dosing with allogeneic UMSCs, reinforcing the potential of an off‑the‑shelf, systemically delivered stem cell approach.
- FDA‑CVM has now granted expanded conditional approval eligibility for both Gallant’s canine and feline OA programs, creating a faster route to market for therapies addressing a significant unmet medical need.
Impact
Marks important momentum for disease‑modifying, cell‑based regenerative therapies in companion animal OA, moving beyond symptomatic pain control toward targeting underlying inflammatory and immune drivers and bringing practical, off‑the‑shelf MSC options closer to everyday veterinary practice.
Advancing Compassion, Welfare, and Responsible Care
The conversation around animal welfare is evolving globally, with increasing awareness of the ethical responsibilities humans hold toward animals across farming, research, entertainment, and companionship. As societies become more conscious of humane practices, ethical treatment of animals is emerging as a critical pillar of sustainability, public health, and social responsibility. This shift reflects a growing commitment to ensuring that animals are treated with dignity, compassion, and respect throughout their lives.
One of the most significant developments in animal welfare is the adoption of higher standards of care in agriculture and livestock management. Consumers are increasingly demanding transparency regarding how animals are raised, transported, and processed. Ethical farming practices now emphasize adequate living conditions, proper nutrition, reduced stress, and freedom from unnecessary suffering. Concepts such as cage-free housing, humane handling, and antibiotic stewardship are becoming more prominent as the industry aligns with evolving consumer expectations and regulatory frameworks.
Scientific research and testing practices are also undergoing transformation through the promotion of humane alternatives. The principles of the “3Rs”—Replacement, Reduction, and Refinement—are guiding organizations toward minimizing animal use in research while improving welfare standards where animal studies remain necessary. Advances in cell-based testing, organ-on-chip technologies, and computer modeling are helping reduce dependence on animal experimentation, supporting both ethical progress and scientific innovation.
Companion animal welfare has gained renewed attention as pets are increasingly regarded as family members. Responsible pet ownership now extends beyond basic care to include emotional well-being, preventive healthcare, balanced nutrition, and enrichment activities. Animal shelters and rescue organizations are playing a crucial role in promoting adoption, vaccination, sterilization, and rehabilitation programs, helping address issues such as abandonment and overpopulation. Public awareness campaigns continue to encourage humane treatment and long-term commitment toward companion animals.
Wildlife conservation and habitat protection remain integral to ethical animal treatment. Rapid urbanization, climate change, and habitat destruction are threatening biodiversity worldwide. Conservation initiatives are focusing on protecting natural ecosystems, preventing illegal wildlife trade, and reducing human-animal conflict. Ethical tourism practices, wildlife rehabilitation, and stronger environmental policies are contributing to more sustainable interactions between humans and wildlife populations.
Technology and innovation are further supporting advancements in animal welfare. Smart monitoring systems, wearable health devices, and precision livestock technologies are enabling better tracking of animal health, behavior, and environmental conditions. These tools help caregivers identify stress, illness, or welfare concerns earlier, improving overall quality of care while supporting humane management practices.
Sustainability is becoming closely linked with ethical treatment of animals. Consumers and organizations alike are recognizing the importance of balancing animal welfare with environmental stewardship and responsible resource use. Ethical sourcing, sustainable farming methods, and cruelty-free product development are gaining momentum as part of broader environmental and social governance initiatives.
In conclusion, the ethical treatment of animals is becoming an increasingly important priority across industries and communities worldwide. Through stronger welfare standards, scientific innovation, responsible ownership, and sustainable practices, society is moving toward a more compassionate and balanced relationship with animals. As awareness and accountability continue to grow, the focus remains on fostering systems that prioritize both animal well-being and long-term ecological harmony.
Product Launch
Jaguar Health plans to launch Neonorm Dog, a non-prescription, plant-based digestive health product formulated for dogs, expanding its existing Neonorm gastrointestinal health franchise beyond foals and calves. Like Neonorm Foal and Neonorm Calf, Neonorm Dog contains a standardized botanical extract from the sustainably harvested Croton lechleri tree and is designed to act locally within the gastrointestinal tract.
Key Highlights
- The product targets growing demand for plant-based, non-antibiotic gastrointestinal support solutions that can be easily integrated into routine canine wellness, offering dog owners an over-the-counter option to help maintain normal stool consistency, digestive balance, and gut hydration.
- Neonorm Dog is positioned to complement Jaguar’s prescription GI portfolio, including Canalevia-CA1 and crofelemer-based programs, by broadening its reach into the companion animal wellness segment through engagement with pet owners, veterinarians, retailers, and online pet health channels.
Impact
Reinforces the industry-wide shift toward plant-based, non-antibiotic digestive health solutions in companion animals, as pet owners and veterinarians increasingly prioritize preventive gastrointestinal support to enhance everyday wellness and reduce reliance on traditional antibiotic approaches.
Research Breakthrough
VolitionRx has submitted a clinical manuscript for peer review detailing the strong diagnostic performance of its Nu.Q Vet Feline prototype assay, a blood-based liquid biopsy test designed to detect lymphoma in cats.
At 97% specificity, the assay detected 86% of feline lymphomas, positioning it to become one of the first simple, affordable liquid biopsy options for feline cancer if successfully commercialized.
Key Highlights
- The assay targets circulating H3.1 nucleosomes as a biomarker, with the study showing significantly higher nucleosome levels in cats with intermediate-to-large cell lymphoma compared with healthy controls, supporting its use as a screening tool for the most common feline cancer.
- Publication of the study in a peer-reviewed journal is expected to trigger a $5M contractual milestone payment, with Volition planning commercialization via reference laboratories and point-of-care platforms, potentially doubling its companion animal addressable market when added to the already-available Nu.Q Vet Canine test in more than 20 countries.
Impact
Represents a major step toward routine, minimally invasive cancer screening in cats by enabling earlier detection of lymphoma, supporting more timely intervention, and advancing the broader adoption of precision liquid biopsy diagnostics in companion animal oncology.
Program Launch
Phibro has introduced its Sustainable Solutions Platform (SSP), a companywide initiative aimed at helping livestock, aquaculture, dairy, and petfood producers cut greenhouse gas emissions using practical, science-based nutrition solutions that fit existing feed and production systems.
Key Highlights
- As part of SSP, Phibro launched Verratain Verified Sustainability Solutions, a new master brand anchored by two low‑carbon microalgae feed ingredients- Verratain Spirulina and Verratain Omega Oil, developed through a strategic partnership with VAXA Technologies.
- Produced in VAXA’s indoor Icelandic facility using renewable geothermal energy, clean water, controlled cultivation, and life-cycle assessment–based methods, these ingredients are designed to replace higher‑emission nutrient sources in feed and directly target feed‑related Scope 3 emissions, typically the largest emissions source for animal protein producers.
- Phibro expects initial commercial sales of Verratain products in the coming months and has appointed sustainability leader Peter Bunce to drive platform development as producers and downstream food companies pursue aggressive value‑chain emission reduction and transparent decarbonization strategies.
Impact
Positions Phibro as a provider of climate-smart production tools that sit alongside traditional animal health and nutrition offerings, using microalgae-based feeds to help reduce carbon intensity while supporting animal performance and supply chain resilience across livestock and petfood markets.
Brand Initiative
Pet Honesty has introduced The Honest Difference, a brand promise focused on scientific validation, ingredient transparency, and measurable wellness outcomes, designed to help pet parents navigate a crowded and claims-heavy pet supplement market.
Key Highlights
- The Honest Difference is built on clinically validated ingredients, independent third-party testing, in‑home product performance studies, and palatability-focused formulations, all underpinned by clean-label standards that exclude corn, wheat, soy, cellulose, palm oil, and artificial flavors and colors.
- Pet Honesty’s proprietary Pure Vitality Blend combines natural bases such as pumpkin and sweet potato with clinically studied actives including Green Lipped Mussel, Calcium Fructoborate (FruiteX‑B), probiotics, and postbiotics to support digestive, immune, oral, bone, and joint health in dogs and cats.
- The company’s validation framework includes post‑production ingredient verification, dose consistency testing, third‑party in‑home use studies, and oversight by its Science and Health Advisory Council of veterinarians and pet health experts.
Impact
Supports the shift toward evidence‑based, clean‑label companion animal wellness by pairing rigorous science and transparency with high palatability and compliance, reinforced by a pledge to donate 1 million dollars in product over the next two years and a nationwide campaign across digital, retail, social, and streaming channels.
Product Launch
PetMade has introduced a new line of veterinarian-approved cardiovascular support supplements formulated to help maintain healthy circulation, cellular energy production, and overall vitality in dogs, with a particular focus on aging pets and breeds predisposed to heart concerns.
Key Highlights
- The formulas combine bioavailable CoQ10 and pure Omega-3 fatty acids—clinically studied nutrients that support heart muscle function, cellular energy metabolism, and a balanced inflammatory response to promote long-term cardiovascular health.
- Developed by PetMade’s veterinary team, the supplements are positioned as proactive daily support for senior dogs and higher-risk breeds, targeting healthy circulation, cardiovascular function, and day-to-day energy and mobility.
Impact
Aligns with the broader shift toward preventive, nutrition-based companion animal wellness, as pet owners increasingly seek science-backed, heart-focused supplements to support healthy aging and quality of life in their dogs.
Creating a More Humane Future for Animals Worldwide
This edition explores the growing global focus on ethical animal treatment across agriculture, research, companion care, and wildlife conservation. Rising consumer awareness, sustainable practices, and scientific innovation are driving more humane standards in animal welfare. The newsletter also highlights major industry developments, including Gallant’s stem cell therapy progress for canine osteoarthritis, Jaguar Health’s plant-based digestive wellness launch, VolitionRx’s feline cancer liquid biopsy breakthrough, Phibro’s sustainability platform for animal nutrition, and new science-backed pet wellness initiatives from Pet Honesty and PetMade.
The Pulse of Global Animal Health
Enjoyed this edition? Share it with colleagues, partners, and fellow leaders shaping the future of animal health.
The industry is evolving at remarkable speed—from breakthrough biotech partnerships and regulatory milestones to AI-driven diagnostics and next-generation veterinary innovations. Staying informed isn’t just valuable—it’s essential to staying ahead.
Forward this newsletter, repost it, and help foster a more connected, informed, and forward-thinking global animal health community.
